SCHEMBL11029039

SCHEMBL11029039

CN1CCN(c2ccc(Nc3cc(Cc4c(F)cccc4Cl)cnc3C(N)=O)cc2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 2/20 0.52
▸ JAK1 P23458 1/20 0.52
▸ TYK2 P29597 1/20 0.52
▸ JAK3 P52333 1/20 0.52
▸ SLC2A1 P11166 1/20 0.51
▸ LCK P06239 1/20 0.47
▸ MAPK14 Q16539 1/20 0.47
▸ WEE1 P30291 1/20 0.46
▸ NTRK1 P04629 1/20 0.46
▸ CSF1R P07333 3/20 0.45
▸ CDK11A Q9UQ88 5/20 0.45
▸ CDK4 P11802 4/20 0.45
▸ CCND1 P24385 4/20 0.45
▸ CCNT1 O60563 4/20 0.45
▸ CDK9 P50750 4/20 0.45
▸ CDK6 Q00534 3/20 0.45
▸ ALK Q9UM73 2/20 0.45
▸ LTK P29376 1/20 0.45
▸ CLK2 P49760 1/20 0.45
▸ GSK3A P49840 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11030740 0.94 SLC2A1 (0.55) JAK2JAK1TYK2JAK3SLC2A1
SCHEMBL11027579 0.94 SLC2A1 (0.49) JAK2JAK1TYK2JAK3SLC2A1
SCHEMBL11033146 0.87 ALK (0.58) JAK2JAK1JAK3CDK11ACDK4
SCHEMBL11033167 0.86 BTK (0.48) JAK2JAK1TYK2JAK3SLC2A1
SCHEMBL11033990 0.86 SLC2A1 (0.54) JAK2JAK1TYK2JAK3SLC2A1
SCHEMBL11028029 0.84 CDK4 (0.53) JAK3SLC2A1NTRK1CSF1RCDK11A
SCHEMBL11029481 0.84 SLC2A1 (0.52) JAK2JAK3SLC2A1LCKMAPK14
SCHEMBL11029685 0.83 CSF1R (0.49) SLC2A1NTRK1CSF1RCDK4CCND1
SCHEMBL11027886 0.83 SLC2A1 (0.47) JAK1JAK3SLC2A1CSF1RCDK11A
SCHEMBL11029579 0.83 JAK2 (0.47) JAK2JAK1TYK2JAK3SLC2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US claimed
EP-2665711-A1 PICOLINAMIDE INHIBITORS OF KINASES Abbvie Inc. (US) 2013-11-27 — — EP claimed
CN-103380117-A Picolinamide inhibitors of kinases ABBOTT LAB 2013-10-30 — — CN claimed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US claimed
WO-2012100135-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — WO claimed
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US disclosed
EP-2665711-A1 PICOLINAMIDE INHIBITORS OF KINASES Abbvie Inc. (US) 2013-11-27 — — EP disclosed
CN-103380117-A Picolinamide inhibitors of kinases ABBOTT LAB 2013-10-30 — — CN disclosed
WO-2012100135-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — WO disclosed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ALK, PKN2, ERBB2 JAK2 83/4885JAK1 248/4885TYK2 490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback